Polymorphisms in ABCB1 and CYP19A1 genes affect anastrozole plasma concentrations and clinical outcomes in postmenopausal breast cancer patients

摘要

AimsAnastrozole, an aromatase inhibitor widely used in breast cancer, has recently been indicated to be a P‐glycoprotein (ABCB1) substrate. We have aimed to determine whether ABCB1 single‐nucleotide polymorphisms (SNPs) can affect anastrozole plasma concentrations in these patients. In addition, we assessed the impact of SNPs in CYP19A1 and TCL1A on the development of arthralgia and cancer recurrence in our series.